DBV Technologies Reports September 30, 2016 Cash Position

MONTROUGE, France–(BUSINESS WIRE)– DBV Technologies, (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock
Market: DBVT), today announced its cash and cash equivalents as of
September 30, 2016.

Cash and cash equivalents

DBV’s cash and cash equivalents amounted to €277.6 million as of
September 30, 2016, compared to €323.4 million as of December 31, 2015.

Number of outstanding and fully diluted shares

As of September 30, 2016, DBV’s number of outstanding
shares was 24,642,828 ordinary shares and on a fully diluted basis¹,
the number of shares was 27,151,653.

About DBV Technologies

DBV Technologies is developing Viaskin®, a proprietary technology
platform with broad potential applications in immunotherapy. Viaskin is
based on epicutaneous immunotherapy, or EPIT®, DBV’s method of
delivering biologically active compounds to the immune system through
intact skin. With this new class of self-administered and non-invasive
product candidates, the company is dedicated to safely transforming the
care of food allergic patients, for whom there are no approved
treatments. DBV’s food allergies programs include ongoing clinical
trials of Viaskin Peanut and Viaskin Milk, and preclinical development
of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical
study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and
exploring potential applications of its platform in vaccines and other
immune diseases.

DBV Technologies has global headquarters in Montrouge, France and New
York, NY as well as New Jersey, CT. Company shares are traded on segment
B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the
SBF120 index, and traded on the Nasdaq Global Select Market in the form
of American Depositary Shares (each representing one-half of one
ordinary share) (Ticker: DBVT). For more information on DBV
Technologies, please visit our website: www.dbv-technologies.com

Forward Looking Statements

This press release may contain forward-looking statements and estimates.
These forward-looking statements and estimates are not promises or
guarantees and involve substantial risks and uncertainties. At this
stage, the products of the Company have not been authorized for sale in
any country. Among the factors that could cause actual results to differ
materially from those described or projected herein include
uncertainties associated generally with research and development,
clinical trials and related regulatory reviews and approvals, the risk
that historical preclinical results may not be predictive of future
clinical trial results, and the risk that historical clinical trial
results may not be predictive of future trial results. A further list
and description of these risks, uncertainties and other risks can be
found in the Company’s regulatory filings with the French Autorité des
Marchés Financiers, the Company’s Securities and Exchange Commission
filings and reports, including in the Company’s Annual Report on Form
20-F for the year ended December 31, 2015 and future filings and reports
by the Company. Existing and prospective investors are cautioned not to
place undue reliance on these forward-looking statements and estimates,
which speak only as of the date hereof. Other than as required by
applicable law, DBV Technologies undertakes no obligation to update or
revise the information contained in this Press Release.

_______________________

¹ fully diluted share capital represents all issued and
outstanding shares, as well as all potential shares which may be issued
upon exercise of outstanding employee warrants, employee free shares and
share options and nonemployee warrants, as approved by DBV Technologies
shareholders and granted by the board of directors.

Image may be NSFW.
Clik here to view.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161102006746/en/